Study of Valproic Acid to Treat HIV Infected Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00312546 |
Recruitment Status
:
Terminated
First Posted
: April 10, 2006
Last Update Posted
: May 14, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Enfuvirtide Drug: Valproic acid | Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | Non-Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Inhibiting Histone Deacetylase: Toward Eradication of HIV |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | April 2009 |
Actual Study Completion Date : | October 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: 2A
Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
|
Drug: Enfuvirtide
90 mg subcutaneously twice daily
Other Name: T-20
|
Experimental: 2B
Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
|
Drug: Valproic acid
500 to 750 mg, taken orally twice daily
|
Experimental: 3A
VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
|
Drug: Enfuvirtide
90 mg subcutaneously twice daily
Other Name: T-20
Drug: Valproic acid
500 to 750 mg, taken orally twice daily
|
Experimental: 3B
Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
|
Drug: Enfuvirtide
90 mg subcutaneously twice daily
Other Name: T-20
|
- Frequencies of replication-competent HIV detected in resting CD4 cells [ Time Frame: At pre-entry and Week 0 to Weeks 12 and 16 ]
- Change in integrated proviral genomes [ Time Frame: Throughout study ]
- Genital tract proviral DNA and viral load [ Time Frame: Throughout study ]
- Detectable viral load during VPA therapy and if it remains undetectable after VPA is discontinued [ Time Frame: Throughout study ]
- HIV-specific antibody changes and CTL responses [ Time Frame: From Week 0 to 16 ]
- Change in replication-competent HIV detected in resting CD4 cells in study participants after intensified HAART, and after extended VPA therapy with or without intensified HAART [ Time Frame: Throughout study ]
- Changes in viral load after intensification of HAART with or without VPA [ Time Frame: Throughout study ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 infected
- Adherent to current HAART regimen
- Adequate vascular access for leukapheresis
- Receiving HAART, defined as at least two nucleoside reverse transcriptase inhibitors plus at least one protease inhibitor or non-nucleoside reverse transcriptase inhibitor, without changes to the regimen within 24 weeks of study entry
- Viral load more than 50 copies/ml on two consecutive occasions for more than 6 months, and less than 200 copies/ml on occasion for more than 6 months prior to study entry
- CD4 count more than 300 cells/mm3
- Willing and able to comply with all study requirements
- Willing to use acceptable forms of contraception
Exclusion Criteria:
- Currently receiving zidovudine or enfuvirtide
- Require certain medications known to interact with valproate (e.g., lamotrigine; barbiturates; carbamazepine; prescription dosages of salicylates, hydantoins, felbamate, and clonazepam)
- Any medical, psychiatric, or job-related responsibility that would interfere with the study. More information about this criterion can be found in the protocol.
- Contraindications to taking VPA (e.g., pregnancy, bleeding disorders, history of pancreatitis, history of hepatitis)
- Receiving interferon, other immunomodulators, or other experimental medications
- Abnormal liver enzyme tests
- Hepatitis B virus infected
- Symptoms of hepatic decompensation
- Blood transfusions or hematopoietic growth factors within 90 days prior to study entry
- Systemic cytotoxic chemotherapy, investigational agents, or immunomodulators within 90 days prior to study entry
- Current drug or alcohol abuse that, in the opinion of the site investigator, would interfere with the study
- Serious illness requiring systemic treatment or hospitalization within 90 days prior to study entry
- Treatment for a current AIDS-defining opportunistic infection within 90 days prior to screening
- Anemic
- Involuntarily incarcerated for treatment of either a psychiatric illness or physical illness (e.g., infectious disease)
- Pregnancy or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00312546
United States, North Carolina | |
University of North Carolina Memorial Hospital | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | David M. Margolis, MD | University of North Carolina, Chapel Hill |
Publications:
Responsible Party: | University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00312546 History of Changes |
Other Study ID Numbers: |
U01AI067854-02 ( U.S. NIH Grant/Contract ) CID 0703 7R01AI064074-01A1 ( U.S. NIH Grant/Contract ) 7R01AI045297-08 ( U.S. NIH Grant/Contract ) U01A125868 |
First Posted: | April 10, 2006 Key Record Dates |
Last Update Posted: | May 14, 2012 |
Last Verified: | May 2012 |
Keywords provided by University of North Carolina, Chapel Hill:
Virus Latency Valproic Acid Histone Deacetylase |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Valproic Acid Enfuvirtide Anticonvulsants Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs HIV Fusion Inhibitors Viral Fusion Protein Inhibitors Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |